About

Enthea works at the intersection of psychedelic medicine and employer benefits, designing health benefit plans that cover ketamine-assisted therapy and building the infrastructure to include psilocybin-assisted therapy as regulatory pathways open. The organization partners with self-insured employers — typically mid-to-large employers who bear the full cost of employee healthcare — to add ketamine-assisted therapy coverage as a mental health benefit.

The insurance gap in psychedelic medicine is one of the most significant access barriers: Oregon's licensed psilocybin service centers cost $1,500-$3,500 per session out of pocket, with no insurance coverage. Enthea's employer benefit model doesn't solve the full access problem, but it represents the first systematic attempt to bring third-party coverage to psychedelic therapy in the United States.

Enthea also provides employer education on the evidence base for ketamine and psychedelic-assisted therapy, employee assistance program integration, and provider network development. The organization has positioned itself as the benefits management infrastructure layer for what will eventually be a larger covered therapy market.

Why It Matters

The single biggest practical barrier to psychedelic therapy access in the United States is cost and lack of insurance coverage. Enthea is building the employer benefits infrastructure that could eventually make coverage routine — a prerequisite for mass access.

State Legal Context

See current psilocybin laws in California.

Related